Dosage Optimization and Treatment Outcomes of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson’s Disease: a single center study
Objective: To optimize the dosage of foslevodopa/foscarbidopa continuous subcutaneous infusion (CSCI) therapy for Parkinson’s disease by identifying dosage differences between the continuation and discontinuation groups.…Effects of Dynamic Neuro-Cognitive Imagery on FOG in People with Parkinson’s Disease: a Randomized Clinical Trial
Objective: To compare the effects of an experimental intervention (EI) based on DNI with a control intervention (CI) of equal volume and intensity, excluding MP…Disease Modifying Potential of a Novel ROCK Inhibitor in Rodent Models of Synucleinopathy
Objective: Evaluate the impact of a novel Rho-associated kinase (ROCK) inhibitor on alpha-synuclein (a-syn) pathology, neuroinflammation, and dopamine neurodegeneration in the AAV-a-syn overexpression and a-syn…Zonisamide for Motor Symptoms and OFF-Time Reduction in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: To evaluate the efficacy and safety of zonisamide as an adjunct therapy for improving motor function and reducing OFF-time in patients with Parkinson’s disease…Autonomic Nervous System Dysfunction in Patients with Huntington’s Disease: Preliminary Results Using the COMPASS-31 Scale
Objective: To characterize dysautonomia-related symptoms in Huntington’s disease (HD) gene expansion carriers (HDGECs). Background: Autonomic nervous system (ANS) dysfunction is a recognized feature of HD…Combining Machine Learning and Linear Mixed Models to Estimate Medication Effect in People with Parkinson’s Disease
Objective: To estimate medication effect, as the score difference between MDS-UPDRS III in OFF and ON-state, using a minimal set of clinical features. Background: The…The Effects of Melatonin in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs
Objective: To assess the efficacy of melatonin on motor symptoms, sleep quality, and quality of life in patients with Parkinson's disease (PD) by performing a…Solengepras: An Investigational Therapy with Potential Benefits on Functional and Non-Motor Measures in Parkinson’s Disease (PD)
Objective: Solengepras is a GPR6-inhibitor that is being studied as an investigational treatment for Parkinson’s Disease (PD). Background: GPR6 is a novel G-protein-coupled receptor found…Ferritin-related Brain Iron Deposition in Parkinson’s Disease Involves α-Synuclein Pathology
Objective: To investigate plasma neuron-derived ferritin-containing extracellular vesicles (NDFEVs) differences between Parkinson’s disease (PD) patients and controls, assess their association with brain iron deposition, and explore the…LRRK2 antisense oligonucleotide (BIIB094/ION859) impact on cerebrospinal fluid biomarkers in Parkinson’s disease patients
Objective: To provide novel fluid biomarker results from REASON – a Phase 1 clinical trial testing a LRRK2 antisense oligonucleotide in both LRRK2-Parkinson’s disease and…
- « Previous Page
- 1
- …
- 330
- 331
- 332
- 333
- 334
- …
- 1942
- Next Page »